Series Finale - Episode 51: Three Thousand Every Year

NOV 16, 202617 MIN

Description

Episode 51 · Series Finale · Asbestos: A Conspiracy 4,500 Years in the Making · Danziger & De Llano Episode 51: Three Thousand Every Year The series finale does not pretend nothing changed. U.S. asbestos consumption collapsed, disease rates are falling, and treatment has advanced. But thousands of families still hear the diagnosis every year, legacy exposure remains, and global demand continues. Episode 51 reviews all ten arcs and the standout research behind them, weighs that progress against the work left to do, and leaves listeners with a practical record to build. Key Takeaways Progress is real: USGS estimates U.S. consumption fell from 803,000 metric tons in 1973 to 50 tons in 2025. Worldwide consumption fell from about 2 million tons in 2000 to 930,000 tons in 2025. The title is a rounded count, not a forecast: ACS says about 3,000 U.S. diagnoses annually. The newer project table records 2,709 diagnoses in 2023 and 2,114 deaths in 2024. Rates and recent counts are falling. Rates and counts answer different questions: a 2026 GBD study found age-standardized incidence and mortality down about a third since 1990 while absolute modeled counts increased with population growth and aging. Female burden rose in multiple states. The story is global: IARC estimates 30,618 new cases and 25,372 deaths worldwide in 2022. Demand continues, especially for construction materials in Asia. Medicine has moved, without a cure: CheckMate 743 reported 14% versus 6% five-year survival. Two FDA-approved first-line immunotherapy-based approaches exist for unresectable pleural disease; no validated screening program exists. The systems are still alive: the Fifth Circuit challenge remains pending, EPA's legacy proposal is due June 3, 2027, and Manville raised its payment percentage to 5.6% in September 2026. The handoff is practical: do not blame yourself; build an honest exposure record; get qualified clinical and legal help early enough to matter. FAQ Does the episode claim mesothelioma has not peaked? No. It explicitly rejects that v1 line. CDC says incidence is falling, and the latest table in the project research shows declining recent counts. A separate long-run model finds absolute cases rising with population growth and aging, so the episode keeps rates, modeled counts, and registry counts distinct. Why keep the title “Three Thousand Every Year”? It is the American Cancer Society's rounded summary. The episode also gives the more specific June 2026 USCS figures: 2,709 diagnoses in 2023 and 2,114 deaths in 2024. It makes no exact forecast for next year. What progress does the finale recognize? Dramatically lower U.S. and global consumption, more than 50 WHO member states with legislative bans, falling U.S. incidence, two FDA-approved first-line immunotherapy-based options, and a compensation system whose terms continue to change. What remains unfinished? Long latency, legacy material in buildings, ongoing global demand, unequal burden by sex and state, no validated screening program, and the continuing Fifth Circuit and EPA Part 2 processes. What should a family do after exposure or diagnosis? Do not blame yourself. Preserve employers, dates, products, ships, buildings, renovations, work-clothes and laundry histories, medical and service records, photographs, letters and witness names. Tell a clinician the exposure history and have symptoms assessed. Ask a qualified lawyer or accredited representative how trust claims, lawsuits and benefits fit your history. No outcome is guaranteed. Published Research and Primary Sources USGS Mineral Commodity Summaries 2026: Asbestos American Cancer Society: mesothelioma key statistics CDC: U.S. mesothelioma statistics and falling incidence Edwards et al., U.S. mesothelioma burden 1990–2023 — PMID 42275613 IARC GLOBOCAN 2022: mesothelioma fact sheet WHO: asbestos prevention and control EPA: Asbestos Part 1 chrysotile rule, 89 FR 21970 EPA: Asbestos Part 2 legacy information request and June 3, 2027 proposal date CheckMate 743 five-year update — PMID 41734361 FDA: pembrolizumab with chemotherapy, September 17, 2024 Mesothelioma screening review — PMID 41512380 Manville Trust record and September 2026 payment-percentage increase Lavento and Hornytzkyj: asbestos in early Finnish pottery Hoffman 1918, Bureau of Labor Statistics Bulletin 231 Selikoff and Greenberg, 1991, Kershaw and early asbestosis history — PMID 1825122 Lohrmann v. Pittsburgh Corning and the Sumner Simpson Papers Rodarmel, Illinois appellate opinion, including Saranac record Dave Foster: firm biography Resources AsbestosTrusts.org: source-classified trust data Dave Foster: patient advocacy at Danziger & De Llano Danziger & De Llano: Mesothelioma Episode 51 page and additional resources Episode 51 wiki transcript Asbestos: A Conspiracy 4,500 Years in the Making is a documentary series tracing asbestos from ancient pottery to present-day exposure, treatment and accountability. Episode 51 is the mainline series finale. Attorney Advertising. This episode is general information, not legal or medical advice. Exposure, treatment, benefits and legal rights require case-specific professional review. Asbestos: A Conspiracy 4,500 Years in the Making is sponsored by Danziger & De Llano Mesothelioma Law Firm, a nationwide practice with over 30 years of experience and nearly $2 billion recovered for asbestos victims. If you or someone you love has been diagnosed with mesothelioma, the exposure happened somewhere—and Paul Danziger and Rod De Llano know how to trace it back. For a free consultation, visit https://dandell.com. Resources: → Mesothelioma legal rights: https://dandell.com/mesothelioma/  → Asbestos exposure sources: https://dandell.com/asbestos-exposure/  → Asbestos trust funds ($30B+ available): https://dandell.com/asbestos-trust-funds/  → Free case evaluation: https://dandell.com/contact/  Sister Podcast - MESO: The Mesothelioma Podcast: http://mesotheliomapodcast.com/